Sample Libraries

Our sample libraries contain:

  • more than 250,000 diverse small-molecule compounds
  • a unique library of more than 45,000 natural product extracts
  • a growing library of 7,000-plus FDA-approved drugs and clinical compounds for drug repurposing projects
  • an extensive siRNA library

Except where noted, the samples in our library are in 384-well formats, all DMSO stocks at 2mM, 5mM and 10mM.

Commercial Drug-Like Molecules

Our sample library contains more than 250,000 diverse small molecule compounds, which have been vetted and selected by our medicinal chemists, including:

View the number of compounds that overlap across all our commercial drug-like molecule sets.

Natural Product Extracts

Colorful bacteria collected in Israel.

Our unique library contains more than 45,000 natural product extracts, primarily built over the years through expeditions by LSI faculty member David H. Sherman, the former director of the center. 

These extracts derive from sediments, cyanobacteria and sponges from all over the world — including Papua New Guinea, Costa Rica, Panama, Lake Erie, Lake Huron, Nepal, Peru, Brazil, the Middle East and Antarctica. 

The bacteria used to prepare the samples are phylogenetically characterized using 16S rRNA gene sequence analysis, cell wall composition and fatty acid analysis, menaquinone characterization and genome sequence analysis followed by natural product gene cluster mining.

New compounds are being added to the library all the time.

The LSI's Natural Products Discovery Core will assist researchers with follow-up activities after identifying natural products hits.

Custom Drug Libraries

Our growing, custom-drug libraries can help identify compounds with established safety and efficacy. They include:
  • U-M Chemistry Collection — a library of 900 compounds developed by U-M scientists
  • Chemical Methodology Library Development — a library of 2,500 compounds from developed by researchers at Boston University and the University of Kansas under the National Institute of General Medical Sciences' Chemical Methodology Library Development Program
  • National Cancer Institute Developmental Therapeutics — a collection of more than 3,200 compounds known to be active in oncology targets; of these, 2,200 compounds are available on 384-well plates
  • National Institutes of Health Clinical Collection —a library with 450 compounds that have a history of use in human clinical trials
  • Pathways Collection — a collection of 1,000 compounds from several vendors with known activity related to autophagy, the Wnt Pathway, epigenetics, protein kinases, proteases, oxidation-reduction reactions (REDOX) and cannabinoids; also includes purified natural products

Chemical Fragments

  • Chemical Fragments — a collection of more than 4,200 fragments from various vendors such as Asinex, Life Chemicals, ChemDiv and Pharmablock.  

Fragment screening is an approach that aims to increase the chances of finding chemicals that can target protein-protein interactions or other novel and challenging drug targets by testing small chemical fragments that can bind to the target with low affinity.

This makes it feasible to do screens with a few thousand fragments rather than the hundreds of thousands drug-like compounds that are often screened from diversity libraries.

This collection is maintained in several formats to facilitate many different methods of screening — nuclear magnetic resonance, differential scanning fluorimetry (DSF, ThermoFluor) and label-free biomolecular interaction analysis. This collection also has powder samples available following hit selection from DMSO samples.


We have "smart-pooled" siRNA libraries covering both the human and mouse genomes.